SOMERSET,N.J.,SHANGHAI andSUZHOU,China,Dec. 31,2024 -- Duality Biologics ("DualityBio") announced that,BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074 from DualityBio,securing global development,manufacturing,and commercialization rights for the investigational product. In 2024,DualityBio received an option exercise fee and a milestone payment based on the Phase I dose-escalation advancement.

In July 2023,DualityBio announced an agreement for BeiGene to acquire its exclusive option for a global clinical and commercial license to an investigational,preclinical ADC therapy for patients with select solid tumors. Under the terms of the agreement,DualityBio received an upfront payment,and is eligible for a payment contingent upon BeiGene exercising its option and additional payments based upon the achievement of certain development,regulatory,and commercial milestones,totaling up to $1.3 billion,in addition to tiered royalties.

About DualityBio

Duality Biologics is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADC to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline,DualityBio is conducting multiple global clinical trials across 17 countries,has enrolled over 1,500 patients for multiple clinical-stage ADC candidates.

Additionally,DualityBio have established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse,DualityBio isdeveloping "Super ADCs," including bispecific ADCs,novel-payload ADCs,and autoimmune ADCs. For more information,please visit www.dualitybiologics.com.

Media Contact

PR@dualitybiologics.com